drugset / Trial / NCT05237349
Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
The objective is to investigate the efficacy and safety of Envafolimab combined with chemotherapy in the treatment of metastatic or recurrent gastric adenocarcinoma.
Timeline
- Start
- 2022-03-01
- Primary completion
- 2024-12-01
- Completion
- 2024-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Envafolimab | Monoclonal antibody | 300 mg | Subcutaneous |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |
| Subject | S-1 | Small molecule | 40 mg/m2 | Oral |